POSTER DISCUSSION
Presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, Florida, May 29 – June 1, 2018
The first Canadian naturalistic study in patients with schizophrenia has reported high rates of remission rates and low rates of relapse with long-acting aripiprazole over a one-year period (Oluboka et al. ASCP 2018; abstract). Read More
The University of Buffalo MS group has reported that comorbid cardiovascular disease appears to contribute to more rapid brain tissue loss in patients with multiple sclerosis (Jakimovski et al. Eur J Neurol 2018; epublished August 13, 2018). Read More
Erenumab (Aimovig), a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, has received Health Canada approval for the prevention of migraine in adults who have at least four migraine days per month. This would include patients with episodic (< 15 headache days/month) and chronic migraine (>15 headache days/month, of which >8 are migrainous). The drug is administered by subcutaneous injection once a month. The recommended dose is 70 mg (one injection) per month. Some patients may benefit from a dose of 140 mg qmonthly, administered as two consecutive 70-mg injections. The drug is provided in an autoinjector for patients to self-administer. Read More
An analysis of data from 24 Italian MS centres has identified factors associated with an early change of disease-modifying therapy (Sacca et al. Mult Scler 2018; epublished July 25, 2018). Read More